Back to Current Sarcoma Research

ASSG Endorsed Clinical Study

rEECur

Title International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Objective The objectives of the study are to compare four chemotherapy regimens in recurrent/refractory ES: cyclophosphamide & topotecan, irinotecan & temozolomide, gemcitabine & docetaxel, and high dose ifosfamide, in order to identify the best one for use as a backbone in future treatment with respect to efficacy (imaging response and survival), toxicity and acceptability to patients.
Type Multi-Arm, Multi-Stage (MAMS) randomised phase II / phase III, open-label, international trial
Population Ages 4-49, Recurrent and refractory Ewing sarcoma
Treatment Four chemotherapy regimens in recurrent/refractory ES: cyclophosphamide & topotecan, irinotecan & temozolomide, gemcitabine & docetaxel, and high dose ifosfamide
Phase II and III
Drug / Intervention Four chemotherapy regimens: cyclophosphamide & topotecan, irinotecan & temozolomide, gemcitabine & docetaxel, and high dose ifosfamide
Sponsor Sponsor ASSG/ ANZCHOG
Funding Source MRFF CANTEEN clinical trial grant
Target accrual 525
Expected Completion 2019
Participating Sites Princess Margaret Hospital, Sydney Children's Hospital, Lady Cilento Children's Hospital, Monash Children's Hospital, Starship Children's Hospital
Recruitment Status Recruiting
Numbers Accrued
Publications and Presentations
 
Principal Investigator A/P Marianne Phillips
Contact for Further Information https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000259-99
Contact Phone Number
Last update 26-Oct-2018 08:35 AM 

 

 Find a Sarcoma Study
Find a Sarcoma Specialist
Ask a Question